Literature DB >> 8619540

The response to levodopa in Parkinson's disease: imposing pharmacological law and order.

J G Nutt1, N H Holford.   

Abstract

The seemingly unpredictable response to levodopa in patients with Parkinson's disease can be understood as an interaction between several distinct pharmacological effects of levodopa. The most important are a short-duration response with a half-life of minutes to hours and a long-duration response with a half-life of days, superimposed on diurnal motor variation. A negative response characterized by brief worsening before and after the short-duration response and dyskinesia accentuate the short-duration response. These various responses are modified by disease progression and long-term levodopa therapy. Pharmacodynamic modeling of the short-duration response indicates that with time, the response becomes less graded and small changes in levodopa concentrations can produce big changes in response. In this setting, unpredictability arises from the variation in absorption and distribution of levodopa.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8619540     DOI: 10.1002/ana.410390504

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  57 in total

1.  Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease.

Authors:  C S Palmer; J K Schmier; E Snyder; B Scott
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

Review 3.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Proceedings of the International Symposium on "Levodopa: Back to the Future", April 3-4, 2009, Catania, Italy.

Authors: 
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

5.  Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.

Authors:  Xuebing Cao; Toru Yasuda; Subramaniam Uthayathas; Ray L Watts; M Maral Mouradian; Hideki Mochizuki; Stella M Papa
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

6.  The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.

Authors:  Orazio Schillaci; Mariangela Pierantozzi; Luca Filippi; Carlo Manni; Livia Brusa; Roberta Danieli; Giorgio Bernardi; Giovanni Simonetti; Paolo Stanzione
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-08       Impact factor: 9.236

Review 7.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

8.  Dopaminergic modulation of motor coordinaton in Parkinson's disease.

Authors:  Jaebum Park; Mechelle M Lewis; Xuemei Huang; Mark L Latash
Journal:  Parkinsonism Relat Disord       Date:  2013-09-22       Impact factor: 4.891

Review 9.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

Review 10.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.